Evidence map›Paper›PMID 42845661›Full record

ArticlebioRxiv : the preprint server for biology2026

Programmable genetic control of tumor-colonizing

Jaehyun Lee, Joshua Glazier, Ralph R Weichselbaum, Mark Mimee

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jaehyun LeeDepartment of Microbiology, University of Chicago, Chicago, IL 60637, USA.
Joshua GlazierPritzker School of Molecular Engineering, University of Chicago, Chicago, IL 60637, USA.
Ralph R WeichselbaumDepartment of Radiation and Cellular Oncology, University of Chicago, Chicago, 60637, USA.
Mark MimeeDepartment of Microbiology, University of Chicago, Chicago, IL 60637, USA.ORCID 0000-0002-3083-2671

Funding

Genetically-engineered Bacteria Overcome Therapy ResistanceR01CA292860 · NCI · UNIVERSITY OF CHICAGO · PI Mark Mimee, RALPH R WEICHSELBAUM · 2024 to 2026
$2.9M
Immunoengineering Postdoctoral Training Program - Resubmission - 1T32AI153020 · NIAID · UNIVERSITY OF CHICAGO · PI ALEGRE, MARIA-LUISA, SWARTZ, MELODY ANN · 2021 to 2025
$2.1M
Microbial Engineering to Control the Structure and Function of the Gut Microbiome.R35GM147478 · NIGMS · UNIVERSITY OF CHICAGO · PI Mark Mimee · 2022 to 2026
$2.0M
NCI NIH HHS R01 CA292860NIAID NIH HHS T32 AI153020NIGMS NIH HHS R35 GM147478
6 · The paper itself

Abstract

Engineered bacteria offer a distinct modality for cancer therapy by exploiting the ability of certain species to colonize tumors and deliver therapeutic payloads. Improving their efficacy and safety requires control over bacterial activity after tumor colonization, yet few microbial chassis permit it.

Identifiers

PMID42845661
PMCPMC13640790

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.